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sUmmARy – A male neonate, born at 26 weeks of postmenstrual age, with intracranial he-
morrhage grade iv and thoracic drainage for artificial tension pneumothorax on day 6 of his life 
is presented. despite prior transfusions, the preprocedural hemogram showed marked anemia and 
thrombocytopenia. To reverse thrombocytopenia and to avoid volume overload, the patient was 
administered 110 µg kg-1 of recombinant activated factor vii (rfviia) and drainage of the pneu-
mothorax was performed uneventfully.
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Introduction
massive transfusion of blood components at some 
point leads to a vicious circle of uncontrollable bleed-
ing, acidosis, eventually hypothermia and hypocalce-
mia. if performed within a short time period, it also 
poses a huge volume overload, especially in very pre-
mature neonates.
premature babies often suffer from intracerebral 
hemorrhage, visible on brain ultrasonography (Us). 
grade iv intracerebral hemorrhage in a neonate in-
volves intraparenchymal hemorrhage. The surround-
ing injured brain tissue is rich in tissue thromboplas-
tin, a potent activator of extrinsic coagulation cascade 
leading to the formation of a fibrin clot. The damaged 
vascular endothelium of the brain activates platelets 
and the intrinsic clotting cascade, adding to the clot 
formation. both mechanisms, meant to stop local 
cerebral bleeding, may eventually cause thrombocy-
topenia and depletion of coagulation factors at the 
systemic level1-3.
off-label use of the recombinant activated factor 
vii (rfviia) has been extended to the management 
of multiple coagulopathic conditions4. it has also been 
used in non-coagulopathic bleeding conditions5,6, and 
to control bleeding in disorders of platelet count and 
function6,7. The complications associated with the use 
of rfviia are estimated to 1%-2%, mostly thrombo-
ses. patients with arterial or central venous catheters 
run a greater risk.
Case Report
on day 6 of his life, a male newborn weighing 
770 grams, born at 26 weeks of postmenstrual age 
of a twin-pregnancy exhibited sudden deterioration. 
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Transfer to our hospital intensive Care Unit (iCU) 
was requested from the delivery hospital because of 
the right side pneumothorax occurring during me-
chanical ventilation, verified by an x-ray (fig. 1).
At the delivery hospital, the neonatologist per-
formed needle drainage in the second intercostal 
space before transportation to our iCU. At birth, the 
patient’s Apgar score was 7/8. immediately after birth, 
the baby was intubated and put on artificial ventila-
tion. he received a surfactant and vitamin K. intrac-
ranial hemorrhage grade iv was diagnosed by Us on 
day 3 of his life (fig. 2). on the same day, he received 
15 ml of fresh frozen plasma (ffp). 
on day 4 of his life, the hemoglobin fell to 4.3 g 
dl-1 from the birth level of 11.3 g dl-1, so he received 
15 ml of packed red cells (pRC). because of elevated 
C-reactive protein (56 mg l-1), the patient was treated 
with antibiotics. diuresis was stimulated with 3 µg 
kg-1 min-1 of dopamine. shortly before transportation 
to our hospital, his hemogram was measured: hemo-
globin was low (8.3 g dl-1) and platelet count was 
66,000 µl-1.
on day 6, the baby was transported to our iCU, 
placed in an incubator, intubated and ventilated with 
fio2 1.0, with dopamine infusion via wrist vein. Con-
sidering thrombocytopenia and low hemoglobin level, 
and in an attempt to avoid hypervolemia and possible 
coagulopathy by transfusion of blood components, 
the baby was administered 110 µg kg-1 of rfviia (no-
voseven, novo nordisk) shortly upon arrival to our 
iCU. Upon admission to the iCU, the pneumotho-
rax was drained. The baby was rested on synchronous 
ventilation and in the next few hours we were able to 
lower his fio2 because of the very good sao2. Upon 
rfviia administration, the first hemoglobin was 7.3 
g dl-1, but platelet count rose to 120,000 µl-1 (Table 
1). The value of ionized calcium was 0.93 mmol l-1 
on admission and substitution was initiated. diuresis 
was appropriate, so dopamine was stopped. packed 
red cells were ordered later and he received 12 ml, 
causing hemoglobin to rise to 11.6 g dl-1. 
in the morning after arrival to our iCU, Us of the 
brain showed no further progression of hematoma, 
compared to the initial finding (fig. 3).
shortly after thoracic drainage, the lungs re-ex-
panded to the normal volume, as documented by a 
radiograph. on day 3 of admission to our iCU, the 
drain was removed. during his further stay at iCU, 
Fig. 1. Right side pneumothorax.
Fig. 2. Initial cerebral ultrasound.
Fig. 3. Cerebral ultrasonography after the administration of 
rFVIIa.
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the patient developed chronic lung disease (bron-
chopulmonary dysplasia), causing delayed weaning 
from mechanical ventilation. eventually, the baby 
was extubated and transferred to the neuropediatric 
ward for evaluation and handling. At the age of three 
months, he was discharged from the hospital. Regu-
lar future neuropediatric follow up examinations were 
ordered. At the age of four months, brain Us showed 
asymmetric ventriculomegaly, more marked on the 
left side. by the age of one year, a left porencephalic 
cyst emerged. The child was operated on and ven-
triculoperitoneal shunt was performed. Considering 
the patient’s gestational age at birth, his neurological 
development was satisfactory.
Discussion
The treatment with blood derivatives may lead to 
dilutional coagulopathy, hypocalcemia and hyper-
volemia. not many articles report on administering 
rfviia to neonates8,9, especially preterm ones.
in physiologic conditions, rfviia induces hemo-
stasis by binding to the exposed tissue factor at the 
sites of endothelial injury to form a complex that ac-
tivates factor X and produces thrombin. At pharma-
cological doses, rfviia also binds weakly to activated 
platelets without tissue factor assistance to activate 
factor X. in this way, rfviia is thought to augment 
platelet function in quantitative or qualitative disor-
ders. it works specifically at actively bleeding sites3,4,10. 
it is not known what platelet count is necessary for 
rfviia to be efficient. in martinowitz’s guidelines, 
the platelet count of 50,000 µl-1 is recommended 
prior to administering rfviia7.
in one report, the failure of the first dose of rfviia 
to stop the bleeding was potentially ascribed to the 
low platelet count. Upon platelet transfusion, the sec-
ond dose of rfviia stopped the bleeding shortly. The 
authors wondered whether the second dose of rfviia 
could have been avoided with earlier administration of 
rfviia5. in our case, one dose of rfviia was enough 
because the initial platelet count was 66,000 µl-1, 
which is not too low. 
veldman et al. report on two preterm neonates, 
born after 27 and 28 weeks of gestation5. The first pa-
tient was given rfviia on day 25 of his life, and the 
second baby on day 16. both patients were supposed 
to be free from detectable pre-existing coagulopathy. 
because of visceral and pulmonary hemorrhage, both 
babies were administered rfviia during and after 
massive substitutions of blood components in an at-
tempt to normalize coagulation factors and thrombo-
cytopenia. both received rfviia two times, i.e. the 
first baby received 150 and 200 µg kg-1, and the sec-
ond baby 200 µg kg-1 twice. 
our patient was born after 26 weeks of gestation 
and was administered 110 µg kg-1 of rfviia once, 
on day 6 of his life. before rfviia, he was already 
transfused with ffp and pRC. despite transfusion, 
control hemogram was low and accompanied by a 
platelet decrease. Aside from the intracerebral hem-
orrhage, anemia was certainly caused by postpartum 
erythrocyte hemolysis. however, the highest level of 
total bilirubin was 104.8 µmol l-1, which was treated 
with phototherapy. our patient was also hypocalce-
mic, which is known to impede the clotting process. 
Upon administration of rfviia, we observed a rise in 
platelet count from 66,000 to 120,000 µl-1. 
in a study by mayer et al., rfviia was able to 
limit the progression of intracerebral hemorrhage in a 
dose-dependent manner in adult stroke patients, doc-
umented by post-administration computed tomogra-
phy scan11. in our case, following the administration 
of rfviia, no further progression of cerebral hemor-
rhage was noticed on follow up Us on the next day. 
Therapeutic supplementation of rfviia leads to 
faster formation of fibrin clots, denser and more resis-
tant to fibrinolysis than without rfviia10,12. The po-
tential benefits of rfviia compared to conventional 
transfusion treatments are the rapid onset of action, 
minimal infusion volume and short preparation time. 
After administration of rfviia, the coagulation pa-
rameters normalized in no more than 20 minutes13. 
All these advantages made the urgent thoracic drain-
age safer in our case.
small preterm babies have immature hepatic func-
tion, so prothrombin time (pT) and other coagulation 
Table 1. Platelet count and PT/INR before and after 
rFVVIIa administration
before rfviia After 110 µg kg
-1 
rfviia
platelet count (µl-1) 66 000 120 000
pT/inR Unknown 75.5%/1.13
pT/inR = prothrombin time/international normalized Ratio
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parameters differ from older children. it is well known 
that rfviia rises pT (shortens international normal-
ized Ratio, inR). This is, however, a poor laboratory 
monitor of a potential favorable effect of rfviia on 
hemostasis. vitamin K is usually given in an attempt 
to support hepatic maturation, as in our case. The ini-
tial coagulogram in our case was not known because 
it was not ordered in the delivery hospital. we did not 
order pre-rfviia coagulogram either because we did 
not want the child to lose any amount of blood before 
the urgent thoracic drainage. 
After rfviia administration, we measured pT of 
75.5% (inR 1.13). measuring post-rfviia fibrinogen 
level of 100 mg dl-1 indicated that pre-rfvii fibrino-
gen was also within the recommended range (more 
than 50 mg dl-1)7. 
Although rfviia has a short half-life, a bolus of 
more than 120 µg kg-1, close to the dose our patient 
received, is reported to normalize coagulation param-
eters for more than 15 hours14,15.
Conclusion
in this paper, we present a premature newborn 
with intracerebral hemorrhage and pneumothorax. 
The newborn weighed just 770 grams and was ane-
mic and thrombocytopenic. After intravenous admin-
istration of 110 µg kg-1 recombinant activated factor 
viia to this premature neonate, we observed a rise in 
platelet count from 66,000 to 120,000 µl-1, without 
the potentially harmful hypervolemia.
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sažetak
poniŠTenJe TRomboCiTopeniJe i KRvARenJA Kod nedonoŠĆeTA pRimJenom 
ReKombinAnTnog AKTiviRAnog fAKToRA vii: pRiKAZ slUČAJA
J. Jakobović, D. Butković, Lj. Popović, D. Bartolek, M. Stanojević i Z. Barčot
opisuje se muško nedonošće rođeno s 26 tjedana postmenstrualne dobi, s intrakranijskim krvarenjem iv. stupnja, 
u kojega se 6. dana života morala učiniti torakalna drenaža zbog tenzijskog pneumotoraksa. iako je dijete već dobivalo 
transfuzije, u hemogramu je neposredno prije torakalne drenaže bila prisutna značajna anemija i trombocitopenija. s ci-
ljem povećanja broja trombocita bez dodatnog opterećivanja intravaskularnog volumena novorođenče je dobilo 110 µg kg-1 
rekombinantnog aktiviranog faktora vii (rfviia) i potom je pneumotoraks dreniran.
Ključne riječi: Trombocitopenija – dijagnostika; Trombocitopenija – etiologija; Faktor VII – terapijska primjena; Rekombi-
nantne bjelančevine – terapijska primjena; Dojenče, nedonošče; Prikaz slučaja

